Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy

被引：5
|
作者：
Kim, E. J. [1 ]
Yu, K. -S. [2 ]
Na, S. H. [1 ]
Nam, E. Y. [1 ]
Oh, H. S. [1 ]
Kim, M. [1 ]
Yoon, S. H. [2 ]
Lee, J-O [1 ]
Koh, Y. [1 ]
Song, K. -H. [1 ]
Choe, P. G. [1 ]
Cho, J. -Y. [2 ]
Song, S. H. [3 ]
Kim, E. S. [1 ]
Kim, H. B. [1 ]
Bang, S. -M. [1 ]
Kim, N. J. [1 ]
Oh, M. -D. [1 ]
Kim, I. [1 ]
Park, W. B. [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehag Ro, Seoul 03080, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea
来源：
JOURNAL DE MYCOLOGIE MEDICALE | 2017年 / 27卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
Posaconazole; PPI; H-2; blocker; Famotidine; EXPOSURE-RESPONSE; FUNGAL-INFECTIONS; PLASMA; PROPHYLAXIS;
D O I：
10.1016/j.mycmed.2017.08.001
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Absorption of posaconazole oral suspension is influenced by several factors including diet, medications, and mucosal integrity. However, there are few prospective data about which is the most important modifiable factor in routine clinical practice. We prospectively analyzed clinical risk factors associated with low posaconazole trough concentrations in 114 patients receiving anticancer chemotherapy due to acute myeloid leukemia or myelodysplastic syndrome who received posaconazole oral suspension. In multivariate analyses, risk factors for drug level < 500 ng/mL included low calorie intake, mucositis >= grade 2, H-2 blocker famotidine and proton-pump inhibitor. The only significant risk factor for drug level < 700 ng/mL was famotidine use (adjusted relative risk, 3.18; 95% confidence interval, 1.07-9.11; P= 0.038). In conclusion, medication of H-2 blocker famotidine should be cautious in patients with hematologic malignancy receiving posaconazole suspension. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：539 / 542
页数：4
相关论文
共 40 条
  • [31] Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis
    Lewis, Russell E.
    Georgiadou, Sarah P.
    Sampsonas, Fotis
    Chamilos, George
    Kontoyiannis, Dimitrios P.
    MYCOSES, 2014, 57 (01) : 49 - 55
  • [32] Suboptimal vitamin K status and its risk factors in a population of Chinese chronic haemodialysis patients
    Feng, Yunlin
    Ruan, Yizhe
    He, Qiang
    Zhang, Wensong
    Wang, Li
    NEPHROLOGY, 2015, 20 (09) : 625 - 631
  • [33] Epidemiology and Factors Associated with Treatment Success of Invasive Fungal Infections Among Newly Hematologic Malignancy Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant in Thailand
    Weeraphon, Benjabhorn
    Nakaranurack, Chotirat
    Jutivorakool, Kamonwan
    Puttilerpong, Chankit
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 2029 - 2042
  • [34] A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy
    Huang, Xiaojun
    Wang, Fengrong
    Chen, Yuhong
    Liu, Ting
    Wang, Jianxiang
    Hu, Jianda
    Jie, Jin
    Chen, Fangping
    Wang, Shujie
    Shen, Zhixiang
    Yu, Li
    Yu, Kang
    Liang, Yingmin
    FUTURE MICROBIOLOGY, 2012, 7 (02) : 201 - 209
  • [35] Risk factors for post-operative venous thromboembolism in patients with a malignancy of the lower limb
    Kim, S. M.
    Park, J. M.
    Shin, S. H.
    Seo, S. W.
    BONE & JOINT JOURNAL, 2013, 95B (04) : 558 - 562
  • [36] Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis
    Cho, Sung-Yeon
    Lee, Dong-Gun
    Choi, Jae-Ki
    Lee, Hyo-Jin
    Kim, Si-Hyun
    Park, Sun-Hee
    Choi, Su-Mi
    Choi, Jung-Hyun
    Yoo, Jin-Hong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Woo-Sung
    Back, Heejung
    Kang, Sukhyun
    Lee, Eui-Kyung
    CLINICAL THERAPEUTICS, 2015, 37 (09) : 2019 - 2027
  • [37] Detection of drug-resistant Escherichia coli in patients with complicated cystitis: Analysis of risk factors
    Shigehara, Kazuyoshi
    Uchibayashi, Tadao
    Maeda, Emi
    Namiki, Mikio
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (10) : 808 - 812
  • [38] Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation
    Montesinos, Pau
    Sanz, Jaime
    Cantero, Susana
    Lorenzo, Ignacio
    Martin, Guillermo
    Saavedra, Silvana
    Palau, Javier
    Romero, Monica
    Montava, Alberto
    Senent, Leonor
    Martinez, Jesus
    Jarque, Isidro
    Salavert, Miguel
    Cordoba, Juan
    Gomez, Lola
    Weiss, Shirley
    Moscardo, Federico
    de la Rubia, Javier
    Larrea, Luis
    Sanz, Miguel A.
    Sanz, Guillermo F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (06) : 730 - 740
  • [39] Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study
    Kobata, Yasunori
    Yajima, Hiroshi
    Yamao, Junichi
    Tanaka, Yasuhito
    Fukui, Hiroshi
    Takakura, Yoshinori
    MODERN RHEUMATOLOGY, 2009, 19 (06) : 629 - 636
  • [40] Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor
    Tang, Fei-Fei
    Cheng, Yi-Fei
    Xu, Lan-Ping
    Zhang, Xiao-Hui
    Yan, Chen-Hua
    Han, Wei
    Chen, Yu-Hong
    Huang, Xiao-Jun
    Wang, Yu
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (09) : 1655 - 1662
1234